Abstract:
Introduction: There are few randomized clinical trials that studied the effects of omega-3 polyunsaturated fatty acids (ω3 PUFA) on Alzheimer’s Disease (AD). Some of these studies showed that patients with mild cognitive impairment have benefits in the treatment, but none of them showed significant improvement in cognitive function in patients with advanced or moderate AD. All these randomized clinical trials had relatively short duration of supplementation, therefore, one of the reasons that may not have contributed to improvement in patients with moderate and advanced disease would be the short period of study. Animal studies offer better long-term controlled research possibilities, compared to clinical studies. Methods: Therefore, a systematic literature review was conducted that focused on the effects of the relevance of long-term ω3 PUFA supplementation on cognitive impairment and neuronal loss in AD animal models. Results: This systematic review showed that the long term, the ω3 PUFA supplementation decreased the ratio omega-6 / omega-3 reduced neuronal loss in experimental models of AD, as well as improved cognitive function. This effect was more evident in older mice compared to young mice, and compared with males females. Conclusions: These results indicate the importance of new clinical trials be conducted with long-term ω3 PUFA supplementation in patients with AD for possible associations correct dosages in the treatment.
Keywords: Omega-3. Alzheimer’s Disease. Cognition
Authors:
Euglena Lessa Bezerra;
Branteli Martins Machado;
Lucidio Clebeson de Oliveira;
Luciana Cristina Borges Fernandes;
Ianara Mendonça da Costa;
Dinalva Brito de Queiroz;
Amália Cinthia Meneses do Rêgo;
Irami Araújo-Filho and Fausto Pierdoná Guzen